| Project/Area Number |
17K10805
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Nakagawa Takayuki 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (10626261)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
佐藤 賢一 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (10282055)
玉井 恵一 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (40509262)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 肺癌 / Periostin |
|---|
| Outline of Final Research Achievements |
To clarify the role of cancer stem cell in lung cancer, we focus on the following points: 1. The role of periostin, localizes to storma, in lung cancer 2. The role of CD271, which we reported as a cancer stem cell-marker, in lung cancer. In conclusion, both periostin and CD271 promote the proliferation in lung cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果によって、肺癌の新たな治療標的が明らかになった。今後さらに検討を続けることで、肺癌幹細胞特異的な治療薬の開発につなげていく。
|
